All posts tagged GlaxoSmithKlein

redcurrant juice

GSK seeks buyers for Lucozade and Ribena brands — report

UK drugmaker GlaxoSmithKline Plc (LON:GSK) has hired JPMorgan Chase & Co (NYSE:JPM) and Greenhill & Co Inc (NYSE:GHL) to help it offload nutritional drink brands Lucozade and Ribena, a spokesperson told Reuters today. According to the representative, many lenders had …

Continue Reading...
biopharma

UK pharmaceuticals group GSK considers taking full control of US partner Theravance

UK pharmaceuticals maker GlaxoSmithKline Plc (LON:GSK) may take full control of its US partner Theravance Inc (NASDAQ:THRX) if the latter's respiratory drugs get the green light by the

Pharmaceutical manufacturing

Pharmaceuticals giant GSK increase stake in Indian healthcare unit to 73%

UK drug maker GlaxoSmithKline Plc (LON:GSK) said today it had increased its stake in its Indian unit GlaxoSmithKline Consumer Healthcare Ltd to 72.5% from 43.2%, as part

Pharmaceuticals

GSK reaches a deal worth $3.6bn to acquire HGS

British drugmaker GlaxoSmithKline Plc (LON:GSK) reached on Monday a USD3.6bn (EUR2.9bn) deal to buy Human Genome Sciences (NASDAQ:HGSI), or HGS, after it raised its offer for the US

Pharmaceutical manufacturing

British drugs giant GSK could announce a deal for HGS today

British drugmaker GlaxoSmithKline Plc (LON:GSK) is seen to increase to some USD14.00 (EUR11.43) a share, or around USD2.8bn in total, from USD13.00 per share, its bid to buy

biopharmaceuticals

GSK extends further its hostile bid for HGS

British pharma major GlaxoSmithKline plc (LON:GSK) said today it had extended its USD13.00 (EUR10.44) per share hostile takeover bid for US-based Human Genome Sciences Inc (NASDAQ:HGSI), or HGS,

Drug Discovery

Drugs giant GSK to take full control of Cambridge-based Cellzome

British drugmaker GlaxoSmithKline Plc (LON:GSK) said on Tuesday it had struck a deal to buy the shares it does not already own in proteomics technologies developer Cellzome for

Pills

HGS’ board ask shareholders to wait for its recommendation on GSK hostile bid

US biopharmaceutical firm Human Genome Sciences (NASDAQ:HGSI), or HGS, said its board would review the unsolicited USD13.00 (EUR10.03) a share takeover offer from GlaxoSmithKline Plc (LON:GSK) and advised

Powered by WordPress